A Phase 2 interventional study of Pegcetacoplan and Sham Procedure in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 46 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 35th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2015, is one of 43 in phase 2, and was the 41st registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 9 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
This is a Phase II, prospective, multicenter, randomized, single-masked, sham-controlled study to assess the safety, tolerability and evidence of activity of multiple IVT injections of pegcetacoplan in subjects with GA secondary to Age-Related Macular Degeneration.
The study will randomize approximately 240 subjects to obtain at least 200 evaluable subjects across 40 multinational sites.
Subjects will be randomized in a 2:2:1:1 manner to receive pegcetacoplan Monthly (AM), pegcetacoplan Every-Other-Month (AEOM), Sham injection Monthly (SM) or Sham injection Every-Other-Month (SEOM), respectively.
All subjects will return to the clinical site on Day 7 to assess acute safety after the first injection. After that, subjects in the monthly groups will return to the clinical site for additional pegcetacoplan (or Sham) injections and study procedures every month until Month 12. Subjects in the Every-Other-Month groups will return to the clinical site for additional pegcetacoplan (or Sham) injections and study procedures every two months until Month 12. All subjects will return for follow-up visits on Months 15 and 18 (3 and 6 months after last injection, respectively).
Inclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to the study eye only.
Diagnosis of GA of the macula secondary to age-related macular degeneration, confirmed within 14 days prior to randomization by the central reading center (CRC) using Fundus Autofluorescence (FAF) images, as well as the following criteria:
Female subjects must be:
Exclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to the study eye only.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
Drug: Pegcetacoplan
A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
Drug: Pegcetacoplan
Subjects will receive a Sham procedure every month for 12 consecutive months.
Other: Sham Procedure
Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
Other: Sham Procedure
Also known as: APL-2
Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 12.
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.
Time frame: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12
The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) and Month 12.
LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12
The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Time frame: Baseline (Day 1) and Month 12.
LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12
The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Time frame: Baseline (Day 1) and Month 12.
LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12
The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.
Time frame: Baseline (Day 1) and Month 12.
LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12
The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) and Month 12.
Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye
The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.
Time frame: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
This Phase II, randomized, single-masked, sham injection-controlled study in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) was conducted at 47 sites (46 active) in 3 countries between 24 September 2015 and 14 July 2017 (Data cut-off date, Month 12).
| Milestone | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Monthly | Sham EOM |
|---|---|---|---|---|
| Started | 86 | 79 | 41 | 40 |
| Completed | 52 | 60 | 33 | 36 |
| Not completed | 34 | 19 | 8 | 4 |
| Withdrew: Adverse event | 17 | 5 | 3 | 1 |
| Withdrew: Investigator's decision | 5 | 1 | 0 | 0 |
| Withdrew: Sponsor's decision | 1 | 0 | 0 | 1 |
| Withdrew: Subject request | 6 | 5 | 2 | 1 |
| Withdrew: Death | 0 | 2 | 2 | 0 |
| Withdrew: Other | 5 | 6 | 1 | 1 |
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| mm | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 | 0.26 ± 0.025 | 0.28 ± 0.026 | 0.35 ± 0.025 |
A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.
| Participants | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| TEAEs | 65 | 47 | 42 |
| Treatment-related TEAEs | 21 | 11 | 0 |
| Serious TEAEs | 4 | 2 | 1 |
| TEAEs with mild intensity | 36 | 30 | 28 |
| TEAEs with moderate intensity | 23 | 14 | 11 |
| TEAEs with severe intensity | 6 | 3 | 3 |
| TEAEs with life-threatening intensity | 0 | 0 | 0 |
| Death related to TEAEs | 0 | 0 | 0 |
| TEAESIs | 5 | 4 | 0 |
| TEAEs leading to study/treatment discontinuation | 19 | 5 | 3 |
The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
| mm^2 | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12 | 1.49 ± 0.161 | 1.69 ± 0.168 | 2.12 ± 0.161 |
The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
| ETDRS letter score | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12 | -3.31 ± 1.352 | -5.78 ± 1.398 | -4.36 ± 1.364 |
The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
| ETDRS letter score | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12 | -2.73 ± 1.145 | -3.21 ± 1.184 | -0.55 ± 1.150 |
The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.
| ETDRS letter score | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12 | -0.76 ± 1.382 | -2.40 ± 1.424 | -3.72 ± 1.385 |
The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
| mm | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12 | -0.04 ± 0.011 | -0.04 ± 0.012 | -0.06 ± 0.011 |
The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.
| Participants | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye | 14 | 5 | 1 |
Collected over TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegcetacoplan Monthly: Ocular Study Eye | 0/86 (0%) | 4/86 (4.7%) | 51/86 (59.3%) |
| Pegcetacoplan EOM: Ocular Study Eye | 0/79 (0%) | 2/79 (2.5%) | 35/79 (44.3%) |
| Sham Pooled: Ocular Study Eye | 0/81 (0%) | 1/81 (1.2%) | 25/81 (30.9%) |
| Pegcetacoplan Monthly: Ocular Fellow Eye | 0/86 (0%) | 0/86 (0%) | 12/86 (14%) |
| Pegcetacoplan EOM: Ocular Fellow Eye | 0/79 (0%) | 0/79 (0%) | 8/79 (10.1%) |
| Sham Pooled: Ocular Fellow Eye | 0/81 (0%) | 1/81 (1.2%) | 10/81 (12.3%) |
| Pegcetacoplan Monthly: Non-ocular | 0/86 (0%) | 12/86 (14%) | 23/86 (26.7%) |
| Pegcetacoplan EOM: Non-ocular | 2/79 (2.5%) | 23/79 (29.1%) | 18/79 (22.8%) |
| Sham Pooled: Non-ocular | 2/81 (2.5%) | 16/81 (19.8%) | 23/81 (28.4%) |
| Event | Pegcetacoplan Monthly: Ocular Study Eye | Pegcetacoplan EOM: Ocular Study Eye | Sham Pooled: Ocular Study Eye | Pegcetacoplan Monthly: Ocular Fellow Eye | Pegcetacoplan EOM: Ocular Fellow Eye | Sham Pooled: Ocular Fellow Eye | Pegcetacoplan Monthly: Non-ocular | Pegcetacoplan EOM: Non-ocular | Sham Pooled: Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 4/86 | 0/79 | 0/81 |
| FallInjury, poisoning and procedural complications | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 3/81 |
| Atrial fibrillationCardiac disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 2/86 | 2/79 | 0/81 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 2/79 | 0/81 |
| PneumoniaInfections and infestations | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 2/86 | 2/79 | 0/81 |
| EndophthalmitisInfections and infestations | 2/86 | 1/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 |
| Intraocular pressure increasedInvestigations | 1/86 | 1/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 |
| Coronary artery stenosisCardiac disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 1/79 | 0/81 |
| Inguinal herniaGastrointestinal disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 1/79 | 0/81 |
| Peptic ulcerGastrointestinal disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 0/86 | 1/79 | 0/81 |
| Event | Pegcetacoplan Monthly: Ocular Study Eye | Pegcetacoplan EOM: Ocular Study Eye | Sham Pooled: Ocular Study Eye | Pegcetacoplan Monthly: Ocular Fellow Eye | Pegcetacoplan EOM: Ocular Fellow Eye | Sham Pooled: Ocular Fellow Eye | Pegcetacoplan Monthly: Non-ocular | Pegcetacoplan EOM: Non-ocular | Sham Pooled: Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| Vitreous floatersEye disorders | 19/86 | 7/79 | 1/81 | 4/86 | 2/79 | 1/81 | 0/86 | 0/79 | 0/81 |
| Conjunctival haemorrhageEye disorders | 16/86 | 9/79 | 8/81 | 2/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 |
| Eye painEye disorders | 12/86 | 3/79 | 6/81 | 1/86 | 1/79 | 1/81 | 0/86 | 0/79 | 0/81 |
| Neovascular age-related macular degenerationEye disorders | 10/86 | 5/79 | 1/81 | 2/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 |
| Visual impairmentEye disorders | 4/86 | 9/79 | 3/81 | 3/86 | 4/79 | 2/81 | 0/86 | 0/79 | 0/81 |
| Urinary tract infectionInfections and infestations | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 9/86 | 9/79 | 7/81 |
| Intraocular pressure increasedInvestigations | 7/86 | 8/79 | 0/81 | 0/86 | 1/79 | 1/81 | 0/86 | 0/79 | 0/81 |
| Viral upper respiratory tract infectionInfections and infestations | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 2/86 | 3/79 | 8/81 |
| FallInjury, poisoning and procedural complications | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 7/86 | 2/79 | 2/81 |
| HypertensionVascular disorders | 0/86 | 0/79 | 0/81 | 0/86 | 0/79 | 0/81 | 4/86 | 6/79 | 6/81 |
The Intent to Treat (ITT) population included all randomized subjects who received at least one injection of study drug.
| Age, Continuous(years) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Mean | 79.6 ± 7.51 | 81.0 ± 7.55 | 78.4 ± 7.43 | 79.7 ± 7.54 |
| Sex: Female, Male(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Female | 55 | 50 | 49 | 154 |
| Male | 31 | 29 | 32 | 92 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 84 | 76 | 81 | 241 |
| Other | 0 | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 2 | 5 |
| Not Hispanic or Latino | 81 | 76 | 77 | 234 |
| Not Reported | 2 | 0 | 0 | 2 |
| Unknown | 1 | 2 | 2 | 5 |
| Region of Enrollment(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Australia | 12 | 11 | 12 | 35 |
| New Zealand | 3 | 3 | 4 | 10 |
| United States | 71 | 65 | 65 | 201 |
| GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye(millimeter square (mm^2)) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Mean | 8.0 ± 3.84 | 8.9 ± 4.47 | 8.2 ± 4.05 | 8.4 ± 4.12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Jul 2017, 21 months.
Results were first posted in Oct 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2019.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →